Comparative efficacy and safety of basal insulins: A review

Hernando Vargas-Uricoechea; Pablo Aschner

doi:10.1016/j.dsx.2021.102318

Comparative efficacy and safety of basal insulins: A review

Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102318. doi: 10.1016/j.dsx.2021.102318. Epub 2021 Oct 19.

Authors

Hernando Vargas-Uricoechea¹, Pablo Aschner²

Affiliations

¹ Director of Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Carrera 5 # 13N-36, Popayán, Cauca, Colombia. Electronic address: hernandovargas@unicauca.edu.co.
² Pontificia Universidad Javeriana, Research Advisor of the San Ignacio University Hospital and Scientific Director of the Colombian Diabetes Association, Colombia.

PMID: 34695771
DOI: 10.1016/j.dsx.2021.102318

Abstract

Background and aim: To provide an update on the usefulness of basal insulin in patients with type 2 diabetes mellitus.

Methods: We conducted a literature search using PubMed and MEDLINE, BIOSIS, Scopus, EMBASE, ClinicalTrials.gov, Google Scholar, and Springer Online Archives Collection until June 2021.

Results: All basal insulins are similar in efficacy, with only small differences among them in terms of the risk of hypoglycemia.

Conclusions: For type 2 diabetes mellitus, all basal insulins have a similar efficacy, with some advantage of Glar-300 and Deg-100 in reducing the risk of hypoglycemia compared to Glar-100.

Keywords: Degludec; Diabetes; Glargine; Insulin.

Publication types

Comparative Study
Review

MeSH terms

Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Humans
Hypoglycemic Agents / therapeutic use*
Insulin Detemir / therapeutic use*
Insulin Glargine / therapeutic use*
Insulin, Long-Acting / therapeutic use*
Randomized Controlled Trials as Topic / methods
Treatment Outcome

Substances

Hypoglycemic Agents
Insulin, Long-Acting
Insulin Glargine
Insulin Detemir
insulin degludec